The fungus Clonostachys rosea was recognized as an aggressive parasite on other fungi already in the late 1950s. Research into its potential use in biological control of plant diseases soon followed. Today, there are several commercial products based on C. rosea available for biocontrol applications worldwide. Although its mycoparasitic ability has attracted a lot of interest, C. rosea is now viewed as an ecological generalist whose lifestyle also includes plant endophytism, rhizosphere competence and polyphagous ability. Protocols for producing high amounts of C. rosea spores are available for both solid state and liquid fermentation. Low temperature and low moisture content are key factors that influence the shelf life of C. rosea propagules. Products based on C. rosea can be delivered to flowers using bumble bees, applied by spraying or as seed dressing or by incorporation into the soil. Clonostachys rosea is today an established factor in sustainable plant protection strategies.

This paper provides some general views on the current guidelines on the purity of medicinal products, with the purpose of informing the medicinal industry about the Danish Medicines Agency's view on how to establish requirements on impurities in chemicallysynthesised active substances (the Danish Medicine Agency's rules of thumb do not cover nonchemical substances) and medicinal products for human use. It should be emphasized that the points of views represent the Danish Medicines Agency's interpretation of the quality guidelines in question.